Long‐term disease control and safety with the anti‐CCR4 antibody mogamulizumab: Post‐hoc analyses from the MAVORIC trial of patients with previously treated cutaneous T‐cell lymphoma

Detalles Bibliográficos
Autores principales: Bagot, Martine, Dalle, Stéphane, Sokol, Lubomir, Tsianakas, Athansios, Musiek, Amy, Ortiz‐Romero, Pablo L., Poligone, Brian, Duvic, Madeleine, Elmets, Craig, Leoni, Mollie, Dwyer, Karen, Ito, Takahiro, Herr, Fiona, Kim, Youn H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2022
Materias:
Letters
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9539986/
https://www.ncbi.nlm.nih.gov/pubmed/35695215
http://dx.doi.org/10.1111/dth.15634

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9539986/
https://www.ncbi.nlm.nih.gov/pubmed/35695215
http://dx.doi.org/10.1111/dth.15634

Ejemplares similares